Federal Circuit Affirms ITC Finding That Apple Watch Infringes Masimo Blood Oxygen Patents
Briefly

Federal Circuit Affirms ITC Finding That Apple Watch Infringes Masimo Blood Oxygen Patents
"The Federal Circuit stated that the ITC permissibly treated the Masimo Watch as the domestic industry article and reasonably viewed the prototype units as physical articles practicing the asserted claims."
"The CAFC determined that the ITC correctly concluded that Masimo Corporation and Cercacor Laboratories proved that Apple violated Section 337 through the sale and import of certain Apple Watch models."
"The patents cover devices that use light-emitting diodes to emit light into tissue and photodetectors to measure the returned intensity of optical emissions to determine a physiological parameter."
"Masimo introduced its motion- and low-perfusion-tolerant technology in 1995 to address inaccurate readings from conventional noninvasive pulse oximeters, particularly in clinical settings."
The U.S. Court of Appeals for the Federal Circuit affirmed the ITC's determination that Apple violated Section 337 of the Tariff Act of 1930. The court found that Masimo Corporation and Cercacor Laboratories proved Apple infringed on patents related to wearable technology for measuring physiological metrics. The patents involved devices using optical emitters and photodetectors. The CAFC ruled that the ITC's domestic industry determination and infringement findings were valid, and the patents were not unenforceable due to prosecution laches.
[
|
]